Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
CancerBiologics

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1419221

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1419221

Global Cancer Immunotherapy Market - Industry Trends and Forecast to 2031

PUBLISHED:
PAGES: 596 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 4800
PDF (Enterprise License) - Printable/Downloadable
USD 7000

Add to Cart

Description

Table of Contents

List of Tables

The global cancer immunotherapy market is expected to reach USD 231,338.41 million by 2031 from USD 83,575.21 million in 2023, growing at a CAGR of 14.5% during the forecast period of 2024 to 2031.

Market Segmentation

Global Cancer Immunotherapy Market, By Product Type (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus), Application (Lung Cancer, Breast Cancer, Melanoma, Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer, and Others), End User (Hospitals, Oncology Clinics, Homecare, and Others), Form (Intravenous (IV), Intramuscular, and Oral), Distribution Channel (Direct Tenders, Retail Sales, and Pharmacies), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Turkey, Belgium, Netherlands, Switzerland, Denmark, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, New Zealand, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031.

Overview of Global Cancer Immunotherapy Market Dynamics

  • Driver
  • Rising prevalence of cancer incidences
  • Restraint
  • Increasing occurrence of immune-related adverse events
  • Opportunity
  • Growing trend towards combination therapies

Market Players

Some of the major market players operating in the global cancer immunotherapy market are:

  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Janssen Pharmaceutical
  • AstraZeneca
  • Gilead Sciences, Inc.
  • Eli Lilly and Company
  • Amgen Inc.
  • Novartis AG
  • GSK
  • Pfizer Inc.
  • Incyte
Show more

TABLE OF CONTENTS

1 INTRODUCTION 84

  • 1.1 OBJECTIVES OF THE STUDY 84
  • 1.2 MARKET DEFINITION 84
  • 1.3 OVERVIEW OF THE GLOBAL CANCER IMMUNOTHERAPY MARKET 84
  • 1.4 CURRENCY AND PRICING 86
  • 1.5 LIMITATIONS 86
  • 1.6 MARKETS COVERED 86

2 MARKET SEGMENTATION 90

  • 2.1 MARKETS COVERED 90
  • 2.2 GEOGRAPHICAL SCOPE 91
  • 2.3 YEARS CONSIDERED FOR THE STUDY 92
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 93
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 96
  • 2.6 MULTIVARIATE MODELLING 97
  • 2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 97
  • 2.8 MARKET END USER COVERAGE GRID 98
  • 2.9 DBMR MARKET POSITION GRID 99
  • 2.10 VENDOR SHARE ANALYSIS 100
  • 2.11 SECONDARY SOURCES 101
  • 2.12 ASSUMPTIONS 101

3 EXECUTIVE SUMMARY 102

4 PREMIUM INSIGHTS 104

  • 4.1 PESTAL ANALYSIS 107
  • 4.2 PORTERS 5 FORCES 108

5 GLOBAL CANCER IMMUNOTHERAPY MARKET: REGULATIONS 109

6 MARKET OVERVIEW 117

  • 6.1 DRIVERS 119
    • 6.1.1 RISING PREVALENCE OF CANCER INCIDENCES 119
    • 6.1.2 RISING TECHNOLOGICAL ADVANCEMENTS 119
    • 6.1.3 INCREASED UNDERSTANDING OF TUMOR MICROENVIRONMENT 120
    • 6.1.4 RISE IN PATIENT AWARENESS AND DEMAND FOR TARGETED TREATMENT 120
  • 6.2 RESTRAINTS 121
    • 6.2.1 INCREASING OCCURRENCE OF IMMUNE-RELATED ADVERSE EVENTS 121
    • 6.2.2 DEVELOPING RESISTANCE TO CANCER TREATMENT 121
  • 6.3 OPPORTUNITIES 122
    • 6.3.1 GROWING TREND TOWARDS COMBINATION THERAPIES 122
    • 6.3.2 RISING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH TOOLS 122
    • 6.3.3 DEVELOPMENT OF NEXT-GENERATION IMMUNOTHERAPIES 123
  • 6.4 CHALLENGES 124
    • 6.4.1 LACK OF STANDARDIZATION IN BIOMARKER TESTING 124
    • 6.4.2 COMPLEXITY OF DEVELOPING AND IMPLEMENTING PERSONALIZED MEDICINE 124

7 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE 125

  • 7.1 OVERVIEW 126
  • 7.2 CHECKPOINT INHIBITORS 129
    • 7.2.1 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1) 130
    • 7.2.2 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 130
  • 7.3 MONOCLONAL ANTIBODIES 131
    • 7.3.1 NAKED MONOCLONAL ANTIBODIES 132
    • 7.3.2 CONJUGATED MONOCLONAL ANTIBODIES 132
    • 7.3.3 BISPECIFIC MONOCLONAL ANTIBODIES 132
  • 7.4 VACCINES 133
    • 7.4.1 PROPHYLACTIC VACCINES 134
    • 7.4.2 THERAPEUTIC VACCINES 134
  • 7.5 CELL THERAPIES 134
    • 7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 135
    • 7.5.2 T CELL THERAPY 135
  • 7.6 IMMUNOMODULATORS 135
    • 7.6.1 INTERFERONS 136
    • 7.6.2 INTERLEUKINS 136
    • 7.6.3 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR 136
  • 7.7 ONCOLYTIC VIRUS 137

8 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END USER 138

  • 8.1 OVERVIEW 139
  • 8.2 HOSPITALS 142
  • 8.3 ONCOLOGY CLINICS 143
  • 8.4 HOMECARE 143
  • 8.5 OTHERS 144

9 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 145

  • 9.1 OVERVIEW 146
  • 9.2 DIRECT TENDERS 149
  • 9.3 RETAIL SALES 150
  • 9.4 PHARMACIES 150
    • 9.4.1 HOSPITAL 151
    • 9.4.2 RETAIL 151
    • 9.4.3 ONLINE 151

10 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY FORM 152

  • 10.1 OVERVIEW 153
  • 10.2 INTRAVENOUS (IV) 156
  • 10.3 INTRAMUSCULAR 157
  • 10.4 ORAL 157

11 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 158

  • 11.1 OVERVIEW 159
  • 11.2 LUNG CANCER 162
    • 11.2.1 CHECKPOINT INHIBITORS 163
    • 11.2.2 MONOCLONAL ANTIBODIES 163
    • 11.2.3 CELL THERAPIES 163
    • 11.2.4 IMMUNOMODULATORS 163
  • 11.3 BREAST CANCER 164
    • 11.3.1 CHECKPOINT INHIBITORS 164
    • 11.3.2 MONOCLONAL ANTIBODIES 164
    • 11.3.3 CELL THERAPIES 165
    • 11.3.4 IMMUNOMODULATORS 165
  • 11.4 MELANOMA 165
    • 11.4.1 CHECKPOINT INHIBITORS 166
    • 11.4.2 MONOCLONAL ANTIBODIES 166
    • 11.4.3 CELL THERAPIES 166
    • 11.4.4 IMMUNOMODULATORS 166
    • 11.4.5 ONCOLYTIC VIRUS 166
  • 11.5 MULTIPLE MYELOMA 167
    • 11.5.1 CHECKPOINT INHIBITORS 167
    • 11.5.2 MONOCLONAL ANTIBODIES 167
    • 11.5.3 CELL THERAPIES 167
    • 11.5.4 IMMUNOMODULATORS 168
  • 11.6 PROSTATE CANCER 168
    • 11.6.1 CHECKPOINT INHIBITORS 168
    • 11.6.2 MONOCLONAL ANTIBODIES 169
    • 11.6.3 CELL THERAPIES 169
    • 11.6.4 IMMUNOMODULATORS 169
    • 11.6.5 VACCINES 169
  • 11.7 OVARIAN CANCER 169
    • 11.7.1 CHECKPOINT INHIBITORS 170
    • 11.7.2 MONOCLONAL ANTIBODIES 170
    • 11.7.3 CELL THERAPIES 170
    • 11.7.4 IMMUNOMODULATORS 170
  • 11.8 CERVICAL CANCER 171
    • 11.8.1 CHECKPOINT INHIBITORS 171
    • 11.8.2 MONOCLONAL ANTIBODIES 171
    • 11.8.3 VACCINES 172
    • 11.8.4 CELL THERAPIES 172
    • 11.8.5 IMMUNOMODULATORS 172
  • 11.9 STOMACH CANCER 172
    • 11.9.1 CHECKPOINT INHIBITORS 173
    • 11.9.2 MONOCLONAL ANTIBODIES 173
    • 11.9.3 CELL THERAPIES 173
    • 11.9.4 IMMUNOMODULATORS 173
  • 11.10 COLORECTAL CANCER 173
    • 11.10.1 CHECKPOINT INHIBITORS 174
    • 11.10.2 MONOCLONAL ANTIBODIES 174
    • 11.10.3 CELL THERAPIES 174
    • 11.10.4 IMMUNOMODULATORS 174
  • 11.11 HEAD AND NECK CANCER 175
    • 11.11.1 CHECKPOINT INHIBITORS 175
    • 11.11.2 MONOCLONAL ANTIBODIES 175
    • 11.11.3 CELL THERAPIES 175
    • 11.11.4 IMMUNOMODULATORS 176
  • 11.12 OTHERS 176
    • 11.12.1 CHECKPOINT INHIBITORS 176
    • 11.12.2 MONOCLONAL ANTIBODIES 176
    • 11.12.3 VACCINES 177
    • 11.12.4 CELL THERAPIES 177
    • 11.12.5 IMMUNOMODULATORS 177

12 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY REGION 178

  • 12.1 OVERVIEW 179
  • 12.2 NORTH AMERICA 182
    • 12.2.1 U.S. 190
    • 12.2.2 CANADA 198
    • 12.2.3 MEXICO 206
  • 12.3 EUROPE 214
    • 12.3.1 GERMANY 222
    • 12.3.2 FRANCE 230
    • 12.3.3 ITALY 238
    • 12.3.4 SPAIN 246
    • 12.3.5 U.K. 254
    • 12.3.6 SWITZERLAND 262
    • 12.3.7 NETHERLANDS 270
    • 12.3.8 RUSSIA 278
    • 12.3.9 TURKEY 286
    • 12.3.10 POLAND 294
    • 12.3.11 HUNGARY 302
    • 12.3.12 LITHUANIA 310
    • 12.3.13 AUSTRIA 318
    • 12.3.14 IRELAND 326
    • 12.3.15 NORWAY 334
    • 12.3.16 REST OF EUROPE 342
  • 12.4 ASIA-PACIFIC 343
    • 12.4.1 CHINA 352
    • 12.4.2 JAPAN 360
    • 12.4.3 INDIA 368
    • 12.4.4 SOUTH KOREA 376
    • 12.4.5 AUSTRALIA 384
    • 12.4.6 SINGAPORE 393
    • 12.4.7 THAILAND 402
    • 12.4.8 INDONESIA 410
    • 12.4.9 PHILIPPINES 419
    • 12.4.10 MALAYSIA 428
    • 12.4.11 VIETNAM 436
    • 12.4.12 REST OF ASIA-PACIFIC 444
  • 12.5 SOUTH AMERICA 445
    • 12.5.1 BRAZIL 453
    • 12.5.2 ARGENTINA 461
    • 12.5.3 PERU 469
    • 12.5.4 REST OF SOUTH AMERICA 477
  • 12.6 MIDDLE EAST AND AFRICA 478
    • 12.6.1 SOUTH AFRICA 486
    • 12.6.2 SAUDI ARABIA 494
    • 12.6.3 U.A.E. 502
    • 12.6.4 EGYPT 510
    • 12.6.5 ISRAEL 518
    • 12.6.6 OMAN 526
    • 12.6.7 QATAR 534
    • 12.6.8 BAHRAIN 542
    • 12.6.9 REST OF MIDDLE EAST AND AFRICA 550

13 GLOBAL CANCER IMMUNOTHERAPY MARKET, COMPANY LANDSCAPE 551

  • 13.1 COMPANY SHARE ANALYSIS: GLOBAL 551
  • 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 552
  • 13.3 COMPANY SHARE ANALYSIS: EUROPE 553
  • 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 554

14 SWOT ANALYSIS 555

15 COMPANY PROFILES 556

  • 15.1 MERCK & CO., INC. 556
    • 15.1.1 COMPANY SNAPSHOT 556
    • 15.1.2 REVENUE ANALYSIS 556
    • 15.1.3 COMPANY SHARE ANALYSIS 557
    • 15.1.4 PRODUCT PORTFOLIO 557
    • 15.1.5 RECENT DEVELOPMENTS 557
  • 15.2 F. HOFFMANN-LA ROCHE LTD 558
    • 15.2.1 COMPANY SNAPSHOT 558
    • 15.2.2 REVENUE ANALYSIS 558
    • 15.2.3 COMPANY SHARE ANALYSIS 559
    • 15.2.4 PRODUCT PORTFOLIO 559
    • 15.2.5 RECENT DEVELOPMENTS 559
  • 15.3 BRISTOL-MYERS SQUIBB COMPANY 561
    • 15.3.1 COMPANY SNAPSHOT 561
    • 15.3.2 REVENUE ANALYSIS 561
    • 15.3.3 COMPANY SHARE ANALYSIS 562
    • 15.3.4 PRODUCT PORTFOLIO 562
    • 15.3.5 RECENT DEVELOPMENTS 563
  • 15.4 JANSSEN GLOBAL SERVICES, LLC 564
    • 15.4.1 COMPANY SNAPSHOT 564
    • 15.4.2 REVENUE ANALYSIS 564
    • 15.4.3 COMPANY SHARE ANALYSIS 565
    • 15.4.4 PRODUCT PORTFOLIO 565
    • 15.4.5 RECENT DEVELOPMENTS 566
  • 15.5 ASTRAZENECA 567
    • 15.5.1 COMPANY SNAPSHOT 567
    • 15.5.2 REVENUE ANALYSIS 567
    • 15.5.3 COMPANY SHARE ANALYSIS 568
    • 15.5.4 PRODUCT PORTFOLIO 568
    • 15.5.5 RECENT DEVELOPMENTS 569
  • 15.6 ABBVIE INC. 570
    • 15.6.1 COMPANY SNAPSHOT 570
    • 15.6.2 PIPELINE PORTFOLIO 570
    • 15.6.3 RECENT DEVELOPMENTS 570
  • 15.7 AMGEN INC. 571
    • 15.7.1 COMPANY SNAPSHOT 571
    • 15.7.2 REVENUE ANALYSIS 572
    • 15.7.3 PIPELINE PORTFOLIO 572
    • 15.7.4 PRODUCT PORTFOLIO 573
    • 15.7.5 RECENT DEVELOPMENTS 573
  • 15.8 ATARA BIOTHERAPEUTICS, INC. 574
    • 15.8.1 COMPANY SNAPSHOT 574
    • 15.8.2 PIPELINE PORTFOLIO 574
    • 15.8.3 RECENT DEVELOPMENTS 574
  • 15.9 BAYER AG 575
    • 15.9.1 COMPANY SNAPSHOT 575
    • 15.9.2 PIPELINE PORTFOLIO 575
    • 15.9.3 RECENT DEVELOPMENTS 575
  • 15.10 CELLDEX THERAPEUTICS. 577
    • 15.10.1 COMPANY SNAPSHOT 577
    • 15.10.2 PIPELINE PORTFOLIO 577
    • 15.10.3 RECENT DEVELOPMENTS 577
  • 15.11 CELLECTIS 578
    • 15.11.1 COMPANY SNAPSHOT 578
    • 15.11.2 PIPELINE PORTFOLIO 578
    • 15.11.3 RECENT DEVELOPMENTS 578
  • 15.12 GILEAD SCIENCES, INC. 579
    • 15.12.1 COMPANY SNAPSHOT 579
    • 15.12.2 REVENUE ANALYSIS 579
    • 15.12.3 PRODUCT PORTFOLIO 580
    • 15.12.4 RECENT DEVELOPMENTS 580
  • 15.13 GSK PLC. 581
    • 15.13.1 COMPANY SNAPSHOT 581
    • 15.13.2 REVENUE ANALYSIS 581
    • 15.13.3 PRODUCT PORTFOLIO 582
    • 15.13.4 RECENT DEVELOPMENTS 582
  • 15.14 INCYTE. 583
    • 15.14.1 COMPANY SNAPSHOT 583
    • 15.14.2 REVENUE ANALYSIS 583
    • 15.14.3 PRODUCT PORTFOLIO 584
    • 15.14.4 RECENT DEVELOPMENTS 584
  • 15.15 LILLY. 585
    • 15.15.1 COMPANY SNAPSHOT 585
    • 15.15.2 REVENUE ANALYSIS 586
    • 15.15.3 PRODUCT PORTFOLIO 586
    • 15.15.4 RECENT DEVELOPMENTS 587
  • 15.16 NOVARTIS AG 588
    • 15.16.1 COMPANY SNAPSHOT 588
    • 15.16.2 REVENUE ANALYSIS 588
    • 15.16.3 PIPELINE PORTFOLIO 589
    • 15.16.4 PRODUCT PORTFOLIO 589
    • 15.16.5 RECENT DEVELOPMENTS 589
  • 15.17 PFIZER INC. 590
    • 15.17.1 COMPANY SNAPSHOT 590
    • 15.17.2 REVENUE ANALYSIS 590
    • 15.17.3 PRODUCT PORTFOLIO 591
    • 15.17.4 RECENT DEVELOPMENTS 591

16 QUESTIONNAIRE 592

17 RELATED REPORTS 596

Show more

LIST OF TABLES

  • TABLE 1 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022- 2031 (USD MILLION) 129
  • TABLE 2 GLOBAL CHECKPOINT INHIBITORS CANCER IMMUNOTHERAPY IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 129
  • TABLE 3 GLOBAL CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022- 2031 (USD MILLION) 130
  • TABLE 4 GLOBAL CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022- 2031 (UNITS) 130
  • TABLE 5 GLOBAL MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 131
  • TABLE 6 GLOBAL MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022- 2031 (USD MILLION) 131
  • TABLE 7 GLOBAL MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022- 2031 (UNITS) 132
  • TABLE 8 GLOBAL VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 133
  • TABLE 9 GLOBAL VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022- 2031 (USD MILLION) 133
  • TABLE 10 GLOBAL VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022- 2031 (UNITS) 133
  • TABLE 11 GLOBAL CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 134
  • TABLE 12 GLOBAL CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022- 2031 (USD MILLION) 134
  • TABLE 13 GLOBAL CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022- 2031 (UNITS) 135
  • TABLE 14 GLOBAL IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 135
  • TABLE 15 GLOBAL IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022- 2031 (USD MILLION) 136
  • TABLE 16 GLOBAL IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 136
  • TABLE 17 GLOBAL ONCOLYTIC VIRUS IN CANCER IMMUNOTHERAPYMARKET, BY REGION, 2022-2031 (USD MILLION) 137
  • TABLE 18 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022- 2031 (USD MILLION) 142
  • TABLE 19 GLOBAL HOSPITALS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 142
  • TABLE 20 GLOBAL ONCOLOGY CLINICS IN CANCER IMMUNOTHERAPY IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 143
  • TABLE 21 GLOBAL HOMECARE IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 143
  • TABLE 22 GLOBAL OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 144
  • TABLE 23 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 149
  • TABLE 24 GLOBAL DIRECT TENDERS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 149
  • TABLE 25 GLOBAL RETAIL SALES IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 150
  • TABLE 26 GLOBAL PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 150
  • TABLE 27 GLOBAL PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 151
  • TABLE 28 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 156
  • TABLE 29 GLOBAL INTRAVENOUS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 156
  • TABLE 30 GLOBAL INTRAMUSCULAR IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 157
  • TABLE 31 GLOBAL ORAL IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 157
  • TABLE 32 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 162
  • TABLE 33 GLOBAL LUNG CANCERI N CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 162
  • TABLE 34 GLOBAL LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 163
  • TABLE 35 GLOBAL BREAST CANCERI N CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 164
  • TABLE 36 GLOBAL BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 164
  • TABLE 37 GLOBAL MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 165
  • TABLE 38 GLOBAL MELANOMA CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 165
  • TABLE 39 GLOBAL MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 167
  • TABLE 40 GLOBAL MULTIPLE MYELOMA CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 41 GLOBAL PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 168
  • TABLE 42 GLOBAL PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 168
  • TABLE 43 GLOBAL OVARIANC ANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 169
  • TABLE 44 GLOBAL OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 170
  • TABLE 45 GLOBAL CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 171
  • TABLE 46 GLOBAL CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 171
  • TABLE 47 GLOBAL STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 172
  • TABLE 48 GLOBAL STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 172
  • TABLE 49 GLOBAL COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 173
  • TABLE 50 GLOBAL COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 174
  • TABLE 51 GLOBAL HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 175
  • TABLE 52 GLOBAL HEAD & NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 175
  • TABLE 53 GLOBAL OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 176
  • TABLE 54 GLOBAL OTHERS CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 176
  • TABLE 55 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 181
  • TABLE 56 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 182
  • TABLE 57 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 182
  • TABLE 58 NORTH AMERICA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 182
  • TABLE 59 NORTH AMERICA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 183
  • TABLE 60 NORTH AMERICA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 183
  • TABLE 61 NORTH AMERICA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 183
  • TABLE 62 NORTH AMERICA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 183
  • TABLE 63 NORTH AMERICA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 184
  • TABLE 64 NORTH AMERICA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 184
  • TABLE 65 NORTH AMERICA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 184
  • TABLE 66 NORTH AMERICA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 184
  • TABLE 67 NORTH AMERICA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 184
  • TABLE 68 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 185
  • TABLE 69 NORTH AMERICA LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 185
  • TABLE 70 NORTH AMERICA BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 185
  • TABLE 71 NORTH AMERICA MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 186
  • TABLE 72 NORTH AMERICA MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 186
  • TABLE 73 NORTH AMERICA PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 186
  • TABLE 74 NORTH AMERICA OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 186
  • TABLE 75 NORTH AMERICA CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 187
  • TABLE 76 NORTH AMERICA STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 187
  • TABLE 77 NORTH AMERICA COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 187
  • TABLE 78 NORTH AMERICA HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 187
  • TABLE 79 NORTH AMERICA OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 188
  • TABLE 80 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 188
  • TABLE 81 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 188
  • TABLE 82 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 188
  • TABLE 83 NORTH AMERICA PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 189
  • TABLE 84 U.S. CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 190
  • TABLE 85 U.S. CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 190
  • TABLE 86 U.S. CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 190
  • TABLE 87 U.S. CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 190
  • TABLE 88 U.S. MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 191
  • TABLE 89 U.S. MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 191
  • TABLE 90 U.S. MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 191
  • TABLE 91 U.S. VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 191
  • TABLE 92 U.S. VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 191
  • TABLE 93 U.S. VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 192
  • TABLE 94 U.S. CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 192
  • TABLE 95 U.S. CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 192
  • TABLE 96 U.S. CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 192
  • TABLE 97 U.S. IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 192
  • TABLE 98 U.S. IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 193
  • TABLE 99 U.S. IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 193
  • TABLE 100 U.S. CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 193
  • TABLE 101 U.S. LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 193
  • TABLE 102 U.S. BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 194
  • TABLE 103 U.S. MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 194
  • TABLE 104 U.S. MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 194
  • TABLE 105 U.S. PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 194
  • TABLE 106 U.S. OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 195
  • TABLE 107 U.S. CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 195
  • TABLE 108 U.S. STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 195
  • TABLE 109 U.S. COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 195
  • TABLE 110 U.S. HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 196
  • TABLE 111 U.S. OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 196
  • TABLE 112 U.S. CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 196
  • TABLE 113 U.S. CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 196
  • TABLE 114 U.S. CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 197
  • TABLE 115 U.S. PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 197
  • TABLE 116 CANADA CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 198
  • TABLE 117 CANADA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 198
  • TABLE 118 CANADA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 198
  • TABLE 119 CANADA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 198
  • TABLE 120 CANADA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 199
  • TABLE 121 CANADA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 199
  • TABLE 122 CANADA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 199
  • TABLE 123 CANADA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 199
  • TABLE 124 CANADA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 199
  • TABLE 125 CANADA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 200
  • TABLE 126 CANADA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 200
  • TABLE 127 CANADA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 200
  • TABLE 128 CANADA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 200
  • TABLE 129 CANADA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 200
  • TABLE 130 CANADA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 201
  • TABLE 131 CANADA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 201
  • TABLE 132 CANADA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 201
  • TABLE 133 CANADA LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 201
  • TABLE 134 CANADA BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 202
  • TABLE 135 CANADA MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 202
  • TABLE 136 CANADA MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 202
  • TABLE 137 CANADA PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 202
  • TABLE 138 CANADA OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 203
  • TABLE 139 CANADA CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 203
  • TABLE 140 CANADA STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 203
  • TABLE 141 CANADA COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 203
  • TABLE 142 CANADA HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 204
  • TABLE 143 CANADA OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 204
  • TABLE 144 CANADA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 204
  • TABLE 145 CANADA CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 204
  • TABLE 146 CANADA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 205
  • TABLE 147 CANADA PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 205
  • TABLE 148 MEXICO CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 206
  • TABLE 149 MEXICO CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 206
  • TABLE 150 MEXICO CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 206
  • TABLE 151 MEXICO CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 206
  • TABLE 152 MEXICO MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 207
  • TABLE 153 MEXICO MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 207
  • TABLE 154 MEXICO MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 207
  • TABLE 155 MEXICO VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 207
  • TABLE 156 MEXICO VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 207
  • TABLE 157 MEXICO VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 208
  • TABLE 158 MEXICO CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 208
  • TABLE 159 MEXICO CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 208
  • TABLE 160 MEXICO CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 208
  • TABLE 161 MEXICO IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 208
  • TABLE 162 MEXICO IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 209
  • TABLE 163 MEXICO IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 209
  • TABLE 164 MEXICO CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 209
  • TABLE 165 MEXICO LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 209
  • TABLE 166 MEXICO BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 210
  • TABLE 167 MEXICO MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 210
  • TABLE 168 MEXICO MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 210
  • TABLE 169 MEXICO PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 210
  • TABLE 170 MEXICO OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 211
  • TABLE 171 MEXICO CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 211
  • TABLE 172 MEXICO STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 211
  • TABLE 173 MEXICO COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 211
  • TABLE 174 MEXICO HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 212
  • TABLE 175 MEXICO OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 212
  • TABLE 176 MEXICO CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 212
  • TABLE 177 MEXICO CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 212
  • TABLE 178 MEXICO CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 213
  • TABLE 179 MEXICO PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 213
  • TABLE 180 EUROPE CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 214
  • TABLE 181 EUROPE CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 214
  • TABLE 182 EUROPE CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 215
  • TABLE 183 EUROPE CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 215
  • TABLE 184 EUROPE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 215
  • TABLE 185 EUROPE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 215
  • TABLE 186 EUROPE VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 216
  • TABLE 187 EUROPE VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 216
  • TABLE 188 EUROPE CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 216
  • TABLE 189 EUROPE CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 216
  • TABLE 190 EUROPE IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 216
  • TABLE 191 EUROPE IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 217
  • TABLE 192 EUROPE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 217
  • TABLE 193 EUROPE LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 217
  • TABLE 194 EUROPE BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 218
  • TABLE 195 EUROPE MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 218
  • TABLE 196 EUROPE MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 218
  • TABLE 197 EUROPE PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 218
  • TABLE 198 EUROPE OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 219
  • TABLE 199 EUROPE CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 219
  • TABLE 200 EUROPE STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 219
  • TABLE 201 EUROPE COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 219
  • TABLE 202 EUROPE HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 220
  • TABLE 203 EUROPE OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 220
  • TABLE 204 EUROPE CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 220
  • TABLE 205 EUROPE CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 220
  • TABLE 206 EUROPE CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 221
  • TABLE 207 EUROPE PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 221
  • TABLE 208 GERMANY CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 222
  • TABLE 209 GERMANY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 222
  • TABLE 210 GERMANY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 222
  • TABLE 211 GERMANY CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 222
  • TABLE 212 GERMANY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 223
  • TABLE 213 GERMANY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 223
  • TABLE 214 GERMANY MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 223
  • TABLE 215 GERMANY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 223
  • TABLE 216 GERMANY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 223
  • TABLE 217 GERMANY VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 224
  • TABLE 218 GERMANY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 224
  • TABLE 219 GERMANY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 224
  • TABLE 220 GERMANY CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 224
  • TABLE 221 GERMANY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 224
  • TABLE 222 GERMANY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 225
  • TABLE 223 GERMANY IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 225
  • TABLE 224 GERMANY CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 225
  • TABLE 225 GERMANY LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 225
  • TABLE 226 GERMANY BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 226
  • TABLE 227 GERMANY MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 226
  • TABLE 228 GERMANY MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 226
  • TABLE 229 GERMANY PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 226
  • TABLE 230 GERMANY OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 227
  • TABLE 231 GERMANY CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 227
  • TABLE 232 GERMANY STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 227
  • TABLE 233 GERMANY COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 227
  • TABLE 234 GERMANY HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 228
  • TABLE 235 GERMANY OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 228
  • TABLE 236 GERMANY CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 228
  • TABLE 237 GERMANY CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 228
  • TABLE 238 GERMANY CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 229
  • TABLE 239 GERMANY PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 229
  • TABLE 240 FRANCE CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 230
  • TABLE 241 FRANCE CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 230
  • TABLE 242 FRANCE CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 230
  • TABLE 243 FRANCE CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 230
  • TABLE 244 FRANCE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 231
  • TABLE 245 FRANCE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 231
  • TABLE 246 FRANCE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 231
  • TABLE 247 FRANCE VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 231
  • TABLE 248 FRANCE VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 231
  • TABLE 249 FRANCE VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 232
  • TABLE 250 FRANCE CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 232

LIST OF FIGURES

  • FIGURE 1 GLOBAL CANCER IMMUNOTHERAPY MARKET: SEGMENTATION 90
  • FIGURE 2 GLOBAL CANCER IMMUNOTHERAPY MARKET: DATA TRIANGULATION 93
  • FIGURE 3 GLOBAL CANCER IMMUNOTHERAPY MARKET: DROC ANALYSIS 94
  • FIGURE 4 GLOBAL CANCER IMMUNOTHERAPY MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 95
  • FIGURE 5 GLOBAL CANCER IMMUNOTHERAPY MARKET: COMPANY RESEARCH ANALYSIS 95
  • FIGURE 6 GLOBAL CANCER IMMUNOTHERAPY MARKET: INTERVIEW DEMOGRAPHICS 96
  • FIGURE 7 GLOBAL CANCER IMMUNOTHERAPY MARKET: MARKET END USER COVERAGE GRID 98
  • FIGURE 8 GLOBAL CANCER IMMUNOTHERAPY MARKET: DBMR MARKET POSITION GRID 99
  • FIGURE 9 GLOBAL CANCER IMMUNOTHERAPY MARKET: VENDOR SHARE ANALYSIS 100
  • FIGURE 10 GLOBAL CANCER IMMUNOTHERAPY MARKET: SEGMENTATION 103
  • FIGURE 11 RISING PREVALENCE OF CANCER AND RISING TECHNOLOGICAL ADVANCEMENTS ARE EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL CANCER IMMUNOTHERAPY MARKET FROM 2024 TO 2034 104
  • FIGURE 12 CHECKPOINT INHIBITORS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CANCER CHEMOTHERAPY CONSUMABLES MARKET IN 2024 TO 2031 104
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL CANCER IMMUNOTHERAPY MARKET AND ASIA-APCIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031 105
  • FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR GLOBAL CANCER IMMUNOTHERAPY MARKET SERVICE PROVIDERS IN THE FORECAST PERIOD OF 2024 TO 2031 106
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL CANCER IMMUNOTHERAPY MARKET 118
  • FIGURE 16 GLOBAL CANCER IMMUNOTHERAPYMARKET : BY PRODUCT TYPE, 2023 126
  • FIGURE 17 GLOBAL CANCER IMMUNOTHERAPYMARKET : BY PRODUCT TYPE, 2024-2031 (USD MILLION) 127
  • FIGURE 18 GLOBAL CANCER IMMUNOTHERAPYMARKET : BY PRODUCT TYPE, CAGR (2024-2031) 127
  • FIGURE 19 GLOBAL CANCER IMMUNOTHERAPYMARKET : BY PRODUCT TYPE, LIFELINE CURVE 128
  • FIGURE 20 GLOBAL CANCER IMMUNOTHERAPYMARKET : BY END USER, 2023 139
  • FIGURE 21 GLOBAL CANCER IMMUNOTHERAPYMARKET : BY END USER, 2024-2031 (USD MILLION) 140
  • FIGURE 22 GLOBAL CANCER IMMUNOTHERAPYMARKET : BY END USER, CAGR (2024-2031) 140
  • FIGURE 23 GLOBAL CANCER IMMUNOTHERAPYMARKET : BY END USER, LIFELINE CURVE 141
  • FIGURE 24 GLOBAL CANCER IMMUNOTHERAPY MARKET: BY DISTRIBUTION CHANNEL, 2023 146
  • FIGURE 25 GLOBAL CANCER IMMUNOTHERAPY MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 147
  • FIGURE 26 GLOBAL CANCER IMMUNOTHERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 147
  • FIGURE 27 GLOBAL CANCER IMMUNOTHERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 148
  • FIGURE 28 GLOBAL CANCER IMMUNOTHERAPY MARKET: BY FORM, 2023 153
  • FIGURE 29 GLOBAL CANCER IMMUNOTHERAPY MARKET: BY FORM, 2024-2031 (USD MILLION) 154
  • FIGURE 30 GLOBAL CANCER IMMUNOTHERAPY MARKET: BY FORM, CAGR (2024-2031) 154
  • FIGURE 31 GLOBAL CANCER IMMUNOTHERAPY MARKET: BY FORM, LIFELINE CURVE 155
  • FIGURE 32 GLOBAL CANCER IMMUNOTHERAPY MARKET: BY APPLICATION, 2023 159
  • FIGURE 33 GLOBAL CANCER IMMUNOTHERAPY MARKET: BY APPLICATION, 2024-2031 (USD MILLION) 160
  • FIGURE 34 GLOBAL CANCER IMMUNOTHERAPY MARKET: BY APPLICATION, CAGR (2024-2031) 160
  • FIGURE 35 GLOBAL CANCER IMMUNOTHERAPY MARKET: BY APPLICATION, LIFELINE CURVE 161
  • FIGURE 36 GLOBAL CANCER IMMUNOTHERAPY MARKET: SNAPSHOT (2023) 180
  • FIGURE 37 GLOBAL CANCER IMMUNOTHERAPY MARKET: COMPANY SHARE 2023 (%) 551
  • FIGURE 38 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET: COMPANY SHARE 2023 (%) 552
  • FIGURE 39 EUROPE CANCER IMMUNOTHERAPY MARKET: COMPANY SHARE 2023 (%) 553
  • FIGURE 40 ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET: COMPANY SHARE 2023 (%) 554

 

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!